• Episode 28: The importance of primate models to understand CMV vaccine vectors
    May 26 2026

    We talk with Dr. Daniel Malouli, an assistant professor at the Vaccine and Gene Therapy Institute at the Oregon Health and Science University, OR, who studies how virus-host interactions modulate CMV infection and pathogenesis as well as determine the safety and efficacy of CMV-based vaccine vectors.

    Show More Show Less
    38 mins
  • Episode 27: IRGM1 regulation of host immunity during vaccination
    Apr 28 2026

    We talk with Dr. Sumanta Naik, a staff scientist in the Department of Molecular Microbiology at Washington University School of Medicine, who is investigating the role of IRGM1 in type I interferon and B cell responses following vaccination and tuberculosis infection.

    Show More Show Less
    24 mins
  • Episode 26: Harnessing bacterial components for vaccines and therapeutics
    Apr 8 2026

    We talk with Dr. Mario Feldman, Professor of Microbiology at Washington University School of Medicine in St. Louis, MO who studies the pathogenesis of Acinetobacter and the biogenesis of bacterial extracellular vesicles.

    Show More Show Less
    28 mins
  • Episode 25: Understanding the role of T cells to improve vaccination for respiratory pathogens
    Apr 8 2026

    We talk with Dr. Daniel Hoft, Director of the Division of Infectious Diseases, Allergy & Immunology and the Center for Vaccine Development at Saint Louis University School of Medicine in St. Louis, MO who studies the development of T-cell targeting vaccines against mucosally-invasive intracellular pathogens such as tuberculosis and influenza.

    Show More Show Less
    35 mins
  • Episode 24: Understanding Tfh cells to improve vaccine-induced antibody responses
    Apr 8 2026

    We talk with Dr. Michela Locci, Associate Professor of Microbiology at the University of Pennsylvania Perelman School of Medicine in Philadelphia, PA who studies how T follicular helper cells promote optimal germinal cell reactions and antibody responses following vaccination.

    Show More Show Less
    23 mins
  • Episode 23: Developing novel lipid nanoparticles to improve vaccine-induced immune responses
    Mar 27 2026

    We talk with Dr. Namit Chaudhary, a postdoctoral researcher in the Department of Immunology & Microbiology at The Scripps Research Institute, CA, who develops new technologies to generate a safe and effective single-shot lipid nanoparticle-based HIV vaccine.

    Show More Show Less
    23 mins
  • Episode 22: Use of VSV-chimeras to understand emerging virus infection and develop anti-viral countermeasures
    Mar 6 2026

    We talk with Dr. Zhouming Liu, an assistant professor of Molecular Microbiology at Washington University School of Medicine, MO, who studies mechanisms of La Cross virus entry and monoclonal antibody–mediated inhibition of infection.

    Show More Show Less
    30 mins
  • Episode 21: A role for T cells in flavivirus vaccination and pathogenesis
    Jan 27 2026

    We talk with Dr. Annie Elong Ngono, a research instructor in the Center for Vaccine Innovation at the La Jolla Institute for Immunology, CA, who studies the role of T cells in vaccine-mediated protection and neurological disease following flavivirus infection.

    Show More Show Less
    24 mins